Effect of Escitalopram on Serum GDNF and BDNF Levels and 5-HT Level of Brain Tissue of Obsessive–Compulsive Disorder Rats

Guo, Huimin; Huang, Bai-Ling; Wang, Yali; Zhang, Yanyan; Ma, Quangang; Lv, Pei-Pei; Ren, Yuming

doi:10.1007/s10571-020-00788-4

Cited by 10 publications

(3 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, BDNF may also serve as a prognostic factor as OCD subjects under medication elicit increased blood BDNF concentrations when compared to subjects without any drug treatment ( 34 ). It should be noted here that quantification of peripheral BDNF concentrations in blood/serum samples provide a good representation of its expression in the brain tissues, as evidenced from chemical models of OCD induced by dopaminergic antagonist quinpirole in rats ( 35 ). Moreover, serum BDNF concentrations may also be a pertinent biomarker for OCD in children ( 36 ).…”

Section: Brain-derived Neurotrophic Factormentioning

confidence: 98%

Potential biomarkers and therapeutic targets for obsessive compulsive disorder

Ravi,

Vashishth,

Rajesh

et al. 2023

Biochem. med. (Online)

View full text Add to dashboard Cite

Obsessive compulsive disorder (OCD) is a prevalent behavioral disorder with a complex etiology. However, the underlying pathogenic molecular pathways and the associated risk factors are largely obscure. This has hindered both the identification of relevant prognostic biomarkers and the development of effective treatment strategies. Because of the diverse range of clinical manifestations, not all patients benefit from therapies currently practiced in the clinical setting. Nevertheless, several lines of evidence indicate that neurotrophic, neurotransmitter, and oxidative signaling are involved in the pathophysiology of OCD. Based upon evidences from clinical (and pre-clinical studies), the present review paper sets out to decipher the utilities of three parameters (i.e. brain-derived neurotrophic factor; BDNF, noradrenalin-synthesizing enzyme dopamine beta-hydroxylase; DBH; and oxidative damage marker malondialdehyde; MDA) as diagnostic peripheral biomarkers as well as bio-targets for therapeutic strategies. While the data indicates promising results, there is necessitation for future studies to further confirm and establish these. Further, based again on the available clinical data, we investigated the possibilities of exploiting the etiological links between disruptions in the sleep-wake cycle and insulin signaling, and OCD for the identification of potential anti-OCD ameliorative agents with the ability to elicit multimodal effects, including attenuation of the alterations in BDNF, noradrenergic and redox pathways. In this respect, agomelatine and metformin may represent particularly interesting candidates; however, further clinical studies are warranted to establish these as singular or complementary medications in OCD subjects.

show abstract

Section: Brain-derived Neurotrophic Factormentioning

confidence: 98%

Potential biomarkers and therapeutic targets for obsessive compulsive disorder

Ravi,

Vashishth,

Rajesh

et al. 2023

Biochem. med. (Online)

View full text Add to dashboard Cite

show abstract

“…Moreover, OCD is a multidimensional disorder with multiple symptom dimensions that may each have distinct aetiological origins [ 31 , 38 ] and distinct neural circuitry [ 39 ]. There may also be a range of additional neurotransmitters and neuropeptides implicated in OCD (human: [ 40 , 41 ]; animal: [ 42 , 43 ]). Advances in human brain imaging methods have also been important in furthering the field, giving impetus to models of OCD neurocircuitry [ 44 ].…”

Section: Introductionmentioning

confidence: 99%

Use of Post-mortem Brain Tissue in Investigations of Obsessive- Compulsive Disorder: A Systematic Review

Lochner,

Naudé,

Stein

2024

View full text Add to dashboard Cite

Background: Post-mortem examination of the brain is a key strategy to increase our understanding of the neurobiology of mental disorders. While extensive post-mortem research has been under taken on some mental disorders, others appear to have been relatively neglected. Objective: The objective of the study was to conduct a systematic review of post-mortem research on obsessive-compulsive disorder (OCD). Methods: A systematic review was performed in accordance with PRISMA guidelines to provide an overview of quantitative, qualitative, or mixed methods primary research studies on OCD. Search platforms included NCBI Pubmed, SCOPUS, and Web of Science. Results: A total of 52 publications were found, and after the removal of works not meeting the inclusion criteria, six (6) peer-reviewed publications remained. These post-mortem studies have provided data on DNA methylation, cellular and molecular alterations, and gene expression profiling in brain areas associated with OCD. Discussion and Conclusion: Included studies highlight the potential value of post-mortem brains from well-characterized individuals with OCD and suggest the need for additional work in this area.

show abstract

“…BDNF is also considered to play a role in regulating mood and behavior, and abnormalities in the expression of this gene have been involved in major anxiety disorder, depressive disorder, and OCD. Preclinical studies have shown that levels of BDNF are drastically decreased in the serum and brain tissue of rats with obsessive-compulsive disorder compared to a control group ( 4 ). In a clinical study, Maina was the first to demonstrate that levels of serum BDNF were significantly decreased in OCD patients compared to normal controls ( 5 ).…”

Section: Introductionmentioning

confidence: 99%

The Brain-Derived Neurotrophic Factor Val66Met Polymorphism Is Associated With Female Obsessive-Compulsive Disorder: An Updated Meta-Analysis of 2765 Obsessive-Compulsive Disorder Cases and 5558 Controls

et al. 2022

View full text Add to dashboard Cite

Objective: Accumulated evidence has implicated that brain-derived neurotrophic factor (BDNF) gene polymorphisms play a role in the etiology of obsessive-compulsive disorder (OCD). A single nucleotide polymorphism in the coding exon of the BDNF gene at position 66, Val66Met (rs6265), is found to be associated with OCD in different populations, but results linking Val66Met with OCD have been inconsistent and inconclusive. In our study we performed a meta-analysis to further examine whether rs6265 genetic variants are involved in the etiology of OCD.Methods: By searching databases, relevant case-control studies were retrieved; using established inclusion criteria, we selected eligible studies for analysis.Results: Thirteen studies were identified that examined the association between the rs6265 polymorphism and OCD. After statistical analyses, no significant association was found between the rs6265 polymorphism and OCD (OR = 1.07, 95% CI = 1.00–1.15, P = 0.06 for genotype; OR = 1.06, 95% CI = 0.98–1.15, P = 0.15 for allele). However, in gender-specific analysis, female Val carriers might be a risk factor for OCD (OR = 1.36, 95% CI = 1.03–1.80, P = 0.03 for genotype; OR = 1.15, 95% CI = 1.01–1.32, P = 0.04 for allele).Conclusion: Our updated meta-analysis suggests that female carriers of the Val66Met BDNF polymorphism might be more suspectable to develop OCD.

show abstract

Effect of Escitalopram on Serum GDNF and BDNF Levels and 5-HT Level of Brain Tissue of Obsessive–Compulsive Disorder Rats

Cited by 10 publications

References 21 publications

Potential biomarkers and therapeutic targets for obsessive compulsive disorder

Potential biomarkers and therapeutic targets for obsessive compulsive disorder

Use of Post-mortem Brain Tissue in Investigations of Obsessive- Compulsive Disorder: A Systematic Review

The Brain-Derived Neurotrophic Factor Val66Met Polymorphism Is Associated With Female Obsessive-Compulsive Disorder: An Updated Meta-Analysis of 2765 Obsessive-Compulsive Disorder Cases and 5558 Controls

Contact Info

Product

Resources

About